In the asthma cohort, Charcot-Leyden crystal galectin (CLC) revealed the most prominent downregulation in expression in the benralizumab-treated arm across all patients, as well as for eosinophil-high and eosinophil-low patients (> 4-fold, FDR < 0.05). The gene discussed is CLC; the disease is asthma.